Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Oct 28.

Published in final edited form as: Cancer Discov. 2011 Jun 1;1(1):44–53. doi: 10.1158/2159-8274.CD-10-0010

Panel A shows the landmark analysis of overall survival for patients with or without 8-week disease control. The landmark time point is set at 8 weeks, i.e., time 0 is at 8 weeks after randomization. Panel B shows the 8-week disease control rates (in %) by treatment in patients with tumors harboring epidermal growth factor receptor (EGFR) and KRAS mutations.

Panel A shows the landmark analysis of overall survival for patients with or without 8-week disease control. The landmark time point is set at 8 weeks, i.e., time 0 is at 8 weeks after randomization. Panel B shows the 8-week disease control rates (in %) by treatment in patients with tumors harboring epidermal growth factor receptor (EGFR) and KRAS mutations.